What is Zacks Research's Forecast for IRWD FY2025 Earnings?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Zacks Research raised their FY2025 earnings estimates for shares of Ironwood Pharmaceuticals in a report issued on Wednesday, February 12th. Zacks Research analyst R. Department now anticipates that the biotechnology company will earn $0.31 per share for the year, up from their prior forecast of $0.17. The consensus estimate for Ironwood Pharmaceuticals' current full-year earnings is $0.10 per share. Zacks Research also issued estimates for Ironwood Pharmaceuticals' Q4 2025 earnings at $0.20 EPS and FY2026 earnings at $0.35 EPS.

Several other equities research analysts have also recently commented on IRWD. JMP Securities lowered their target price on Ironwood Pharmaceuticals from $23.00 to $14.00 and set a "market outperform" rating for the company in a research note on Thursday, January 30th. Craig Hallum lowered their price target on shares of Ironwood Pharmaceuticals from $10.00 to $8.00 and set a "buy" rating for the company in a research report on Wednesday, January 22nd. Finally, StockNews.com downgraded shares of Ironwood Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, November 12th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $8.60.

Ironwood Pharmaceuticals Stock Down 1.8 %

IRWD stock traded down $0.04 during trading on Monday, hitting $1.91. The company had a trading volume of 1,433,588 shares, compared to its average volume of 3,675,248. The firm has a 50-day moving average price of $3.43 and a 200-day moving average price of $4.00. Ironwood Pharmaceuticals has a 12 month low of $1.59 and a 12 month high of $15.26. The stock has a market cap of $304.85 million, a price-to-earnings ratio of -63.50 and a beta of 0.29.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in IRWD. Pacer Advisors Inc. boosted its position in shares of Ironwood Pharmaceuticals by 26.6% during the third quarter. Pacer Advisors Inc. now owns 11,279,822 shares of the biotechnology company's stock worth $46,473,000 after buying an additional 2,372,183 shares during the period. Stonepine Capital Management LLC lifted its stake in Ironwood Pharmaceuticals by 1,982.8% in the 3rd quarter. Stonepine Capital Management LLC now owns 1,000,000 shares of the biotechnology company's stock valued at $4,120,000 after acquiring an additional 951,988 shares in the last quarter. State Street Corp boosted its position in Ironwood Pharmaceuticals by 7.3% during the 3rd quarter. State Street Corp now owns 9,919,865 shares of the biotechnology company's stock worth $40,870,000 after acquiring an additional 677,024 shares during the last quarter. Deutsche Bank AG grew its stake in shares of Ironwood Pharmaceuticals by 47.4% during the 4th quarter. Deutsche Bank AG now owns 1,567,535 shares of the biotechnology company's stock worth $6,944,000 after acquiring an additional 504,336 shares in the last quarter. Finally, Renaissance Technologies LLC grew its stake in shares of Ironwood Pharmaceuticals by 5.5% during the 4th quarter. Renaissance Technologies LLC now owns 9,066,241 shares of the biotechnology company's stock worth $40,163,000 after acquiring an additional 469,043 shares in the last quarter.

Insider Transactions at Ironwood Pharmaceuticals

In related news, CMO Michael Shetzline sold 41,269 shares of the firm's stock in a transaction on Monday, February 10th. The stock was sold at an average price of $1.76, for a total transaction of $72,633.44. Following the sale, the chief marketing officer now owns 554,007 shares of the company's stock, valued at approximately $975,052.32. This trade represents a 6.93 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Thomas A. Mccourt sold 139,064 shares of Ironwood Pharmaceuticals stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $1.76, for a total value of $244,752.64. Following the transaction, the chief executive officer now owns 1,160,634 shares in the company, valued at approximately $2,042,715.84. This represents a 10.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 192,381 shares of company stock valued at $338,591 over the last three months. 12.90% of the stock is currently owned by corporate insiders.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.